Impel Pharmaceuticals Inc. (NASDAQ:IMPL – Get Rating) – Wedbush issued their FY2027 earnings per share (EPS) estimates for Impel Pharmaceuticals in a research report issued on Monday, January 23rd. Wedbush analyst L. Chico expects that the company will earn $1.16 per share for the year. Wedbush currently has a “Neutral” rating and a $5.00 target price on the stock. The consensus estimate for Impel Pharmaceuticals’ current full-year earnings is ($4.63) per share.
Several other research firms have also weighed in on IMPL. Guggenheim dropped their price target on Impel Pharmaceuticals to $14.00 in a research report on Monday, November 21st. Cowen dropped their price target on Impel Pharmaceuticals to $40.00 in a research report on Thursday, November 17th.
Impel Pharmaceuticals Stock Down 5.3 %
Impel Pharmaceuticals (NASDAQ:IMPL – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.44). The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $5.16 million. Impel Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 701.26%.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Impel Pharmaceuticals by 8.1% in the 1st quarter. Vanguard Group Inc. now owns 531,784 shares of the company’s stock worth $3,387,000 after purchasing an additional 40,032 shares during the last quarter. DCF Advisers LLC increased its position in Impel Pharmaceuticals by 19.5% in the 2nd quarter. DCF Advisers LLC now owns 438,566 shares of the company’s stock worth $4,087,000 after purchasing an additional 71,508 shares during the last quarter. State Street Corp increased its position in Impel Pharmaceuticals by 6.6% in the 1st quarter. State Street Corp now owns 180,045 shares of the company’s stock worth $1,147,000 after purchasing an additional 11,107 shares during the last quarter. Opaleye Management Inc. acquired a new position in Impel Pharmaceuticals in the 2nd quarter worth about $1,348,000. Finally, Millennium Management LLC acquired a new position in Impel Pharmaceuticals in the 2nd quarter worth about $1,344,000. 63.92% of the stock is owned by institutional investors and hedge funds.
About Impel Pharmaceuticals
Impel Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
- Get a free copy of the StockNews.com research report on Impel Pharmaceuticals (IMPL)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
Receive News & Ratings for Impel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.